Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer

Gene Therapy volume 10, pages 1903–1909 (2003)Cite this article

Abstract

Treatments available to women with locally advanced breast cancer are unsatisfactory, since most patients succumb to metastatic spread. Therefore, there is a need to devise novel therapeutic combinations that effectively inhibit metastatization and to test them in animal models of breast cancer showing strong similarities with their human counterpart, including the ability to give rise to metastases. With these considerations in mind, tamoxifen (TAM), 4-hydrotamoxifen (4-HT) or liposome-complexed DNA constructs coding for antiangiogenic/anti-invasion proteins (angiostatin, TIMP-2, IFN-α1, sFLT-1) were individually administered to MMTVneu transgenic mice. Significant inhibition of primary tumor growth was obtained with TAM (40% inhibition, P=0.049), angiostatin (85% inhibition, P=0.001) and TIMP-2 (60% inhibition, P=0.015). No lung metastasis was observed in any of these treated mice at 5 months, compared with a rate of 70% in control groups. These observations were the basis for designing a combined treatment with all these compounds. The association of angiostatin, TIMP-2 and TAM was greatly effective at the primary tumor level (90% inhibition, P=0.01). Moreover, all the mice treated with this association were metastasis free at a time point (6 months) in which seven out of nine control mice were either dead from disseminated cancer or showed lung metastasis. This combined therapy could become an important component of anticancer therapy in humans.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Rubens RD . Management of advanced breast cancer. Int J Clin Pract 2001; 55: 676–679.

    CAS  PubMed  Google Scholar 

  2. Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364.

    Article  CAS  PubMed  Google Scholar 

  3. Hanahan D, Christofori G, Naik P, Arbeit J . Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996; 32A: 2386–2393.

    Article  CAS  PubMed  Google Scholar 

  4. Lee JC et al. Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res 2002; 62: 747–755.

    CAS  PubMed  Google Scholar 

  5. Bergers G et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808–812.

    Article  CAS  PubMed  Google Scholar 

  6. Sacco MG et al. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatisation in a transgenic model of breast cancer. Cancer Res 2000; 60: 2660–2665.

    CAS  PubMed  Google Scholar 

  7. Sacco MG et al. Local regression of breast tumors following intrammamary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Gene Therapy 1995; 2: 493–497.

    CAS  PubMed  Google Scholar 

  8. Sacco MG et al. Partial regression, yet uncomplete eradication of mammary tumors in transgenic mice by retroviral mediated HSV-TK transfer ‘in vivo’. Gene Therapy 1996; 3: 1151–1156.

    CAS  PubMed  Google Scholar 

  9. Sacco MG et al. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice. Gene Therapy 1998; 5: 388–393.

    Article  CAS  PubMed  Google Scholar 

  10. Sacco MG et al. Retroviral-mediated IL-4 gene therapy in spontaneous adenocarcinomas from MMTV-neu transgenic mice. Gene Therapy 1999; 6: 1893–1897.

    Article  CAS  PubMed  Google Scholar 

  11. Sacco MG et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastatisation in MMTVneu transgenic mice. Gene Therapy 2001; 8: 67–70.

    Article  CAS  PubMed  Google Scholar 

  12. Sacco MG et al. Combined effects on tumor growth and metastasis by anti-estrogenic and antiangiogenic therapies in MMTV-neu mice. Gene Therapy 2002; 9: 1338–1341.

    Article  CAS  PubMed  Google Scholar 

  13. Sacco MG et al. Establishment and characterisation of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice. Breast Cancer Res Treat 1998; 47: 171–180.

    Article  CAS  PubMed  Google Scholar 

  14. Montagna C et al. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 2002; 21: 890–898.

    Article  CAS  PubMed  Google Scholar 

  15. O'Reilly MS, Holmgren L, Chen C, Folkman J . Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689–692.

    Article  CAS  PubMed  Google Scholar 

  16. Boehm T, Folkman J, Browder T, O'Reilly MS . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.

    Article  CAS  PubMed  Google Scholar 

  17. Kleiner DE, Stetler-Stevenson PG . Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: 42–51.

    Article  Google Scholar 

  18. Matrisian LM . The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455–463.

    Article  CAS  PubMed  Google Scholar 

  19. Nagase H, Woessner JFJ . Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–21494.

    Article  CAS  PubMed  Google Scholar 

  20. Vu TH et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411–422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Stetler-Stevenson WG . Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237–1241.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhou Z et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000; 97: 4052–4057.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kong HL, Crystal RG . Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90: 273–286.

    Article  CAS  PubMed  Google Scholar 

  24. Cao Y . Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001; 33: 357–369.

    Article  CAS  PubMed  Google Scholar 

  25. Goldman CK et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795–8800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gutterman JU . Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198–1205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Brouty-Boye D, Zetter BR . Inhibition of cell motility by interferon. Science 1980; 208: 516–518.

    Article  CAS  PubMed  Google Scholar 

  28. Slaton JW et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726–2734.

    CAS  PubMed  Google Scholar 

  29. Early Breast Cancer Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998; 351: 1451–1467.

  30. Custodio JB, Dinis TC, Almeida LM, Madeira VM . Tamoxifen and hydroxytamoxifen as intramembranous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity. Biochem Pharmacol 1994; 47: 1989–1998.

    CAS  PubMed  Google Scholar 

  31. Nguyen M, Arkell J, Jackson CJ . Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960–970.

    Article  CAS  PubMed  Google Scholar 

  32. McNamara DA et al. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 2001; 2: 714–718.

    Article  Google Scholar 

  33. Haschek WM, Rousseaux CG . Female reproductive system. In: Fundamental of Toxicologic Pathology. Academic Press: San Diego, CA, 1998, pp 485–514.

    Google Scholar 

  34. Henderson IC et al. Comprehensive management of disseminated breast cancer. Cancer 1990; 66: 1439–1448.

    Article  CAS  PubMed  Google Scholar 

  35. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712.

    Article  CAS  PubMed  Google Scholar 

  36. Xu X et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999; 22: 37–43.

    Article  CAS  PubMed  Google Scholar 

  37. Spring K et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet 2002; 32: 185–190.

    Article  CAS  PubMed  Google Scholar 

  38. Kerbel R, Folkman J . Clinical translation of angiogenesis of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727–739.

    Article  CAS  PubMed  Google Scholar 

  39. Indraccolo S et al. Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. Int J Biol Markers 1999; 14: 251–256.

    Article  CAS  PubMed  Google Scholar 

  40. Indraccolo S et al. Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells. Gene Therapy 2002; 9: 867–878.

    Article  CAS  PubMed  Google Scholar 

  41. DuBridge RB et al. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7: 379–387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Albini A et al. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 1997; 11: 713–721.

    Article  CAS  PubMed  Google Scholar 

  43. Gallacher S, Winston SE, Fuller SA, Hurrell JGR . Immunoblotting and immunodetection. In: Ausubel FM et al (eds). Current Protocols in Molecular Biology. John Wiley & Sons: Canada, 1994, Unit 10.8.1–10.8.17.

    Google Scholar 

  44. Cardiff RD et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000; 19: 968–988.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The technical assistance of L Susani is acknowledged. We thank Fulvio Adorni for statistical analysis. The financial supports of AIRC to MGS, Ministero della Salute to MGS, MIUR Genomica Funzionale to PV and MIUR-FIRB to PV (RBNE019J9W) are gratefully acknowledged. This is manuscript no. 66 of the Genoma 2000/ITBA Project funded by CARIPLO.

Author information

Authors and Affiliations

  1. Department of Human Genome and Multifactorial Diseases, Istituto di Tecnologie Biomediche, ITB-CNR, Segrate, Italy

    M G Sacco, S Soldati, L Cattaneo & P Vezzoni

  2. Department of Veterinary Pathology, Hygiene and Public Health, University of Milan, Milan, Italy

    S Soldati & E Scanziani

  3. IST, Viral and Molecular Oncology Section, Padova, Italy

    S Indraccolo

  4. Centro Ricerche Parco Scientifico “E. Menni”, Ospedale Poliambulanza, Brescia, 25100, Italy

    L Cattaneo

Authors
  1. M G Sacco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Soldati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Indraccolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Mira Cató
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Cattaneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Scanziani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Vezzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sacco, M., Soldati, S., Indraccolo, S. et al. Combined antiestrogen, antiangiogenic and anti-invasion therapy inhibits primary and metastatic tumor growth in the MMTVneu model of breast cancer. Gene Ther 10, 1903–1909 (2003). https://doi.org/10.1038/sj.gt.3302082

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302082

Keywords

This article is cited by

Search

Advanced search

Quick links